As US measles cases rise, biotech firms start developing new treatments
Biotech firms are beginning to develop new treatments for measles as US vaccination rates decline and case numbers reach a 35-year high. While these countermeasures aim to protect vulnerable populations, experts note they are years away from availability and may not reach vaccine-hesitant groups.
Why it matters
The resurgence of preventable diseases due to falling vaccination rates creates a new market for therapeutic interventions, highlighting a shift in public health challenges.
Vaccines save lives As US measles cases rise, biotech firms start developing new treatments The US is making measles great again, so treatment options are needed for the most vulnerable.
6 Signs point the way to measles testing in the parking lot of the Seminole Hospital District across from Wigwam Stadium on February 27, 2025 in Seminole, Texas. Signs point the way to measles testing in the parking lot of the Seminole Hospital District across from Wigwam Stadium on February 27, 2025 in Seminole, Texas. Text settings Story text Size Small Standard Large Width * Standard Wide Links Standard Orange * Subscribers only Learn more Minimize to nav Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in